Bristol-Myers Squibb Company has received European Commission approval for a perioperative regimen involving neoadjuvant Opdivo® (nivolumab) combined with chemotherapy, followed by adjuvant Opdivo for the treatment of resectable, high-risk non-small cell lung cancer (NSCLC) with PD-L1 expression ≥1%. This approval is based on the results from the CheckMate-77T trial, which demonstrated improved event-free survival with this treatment compared to traditional methods. Opdivo is now the only PD-$(L)$1 inhibitor approved for both perioperative and neoadjuvant-only treatment of resectable NSCLC in the European Union. The approval is valid across all 27 EU member states, Iceland, Liechtenstein, and Norway. This development offers a new immunotherapy option for select patients, potentially altering the disease course by significantly reducing cancer recurrence risk and enhancing long-term outcomes.